- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 38/20 - Interleukines
Détention brevets de la classe A61K 38/20
Brevets de cette classe: 5048
Historique des publications depuis 10 ans
|
257
|
331
|
422
|
424
|
511
|
453
|
496
|
430
|
361
|
138
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Iovance Biotherapeutics, Inc. | 366 |
97 |
| The Regents of the University of California | 20587 |
65 |
| Massachusetts Institute of Technology | 10209 |
58 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3272 |
51 |
| Altor BioScience, LLC | 79 |
50 |
| The Board of Trustees of the Leland Stanford Junior University | 6605 |
47 |
| Immunitybio, Inc. | 495 |
46 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3331 |
42 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2976 |
41 |
| Novartis AG | 10341 |
38 |
| The Trustees of the University of Pennsylvania | 4406 |
35 |
| Memorial Sloan-Kettering Cancer Center | 2008 |
35 |
| Nektar Therapeutics | 422 |
35 |
| Regeneron Pharmaceuticals, Inc. | 4632 |
34 |
| Bristol-myers Squibb Company | 4815 |
32 |
| Genentech, Inc. | 4087 |
31 |
| Genexine, Inc. | 109 |
31 |
| Dana-Farber Cancer Institute, Inc. | 2654 |
30 |
| Philogen S.p.A. | 126 |
30 |
| Xencor, Inc. | 408 |
30 |
| Autres propriétaires | 4190 |